Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists test drug mix in healthy volunteers

NCT ID NCT05469113

Summary

This study aimed to understand how taking the cancer drug selpercatinib (LOXO-292) changes how the body absorbs and removes the diabetes drug repaglinide. It involved 16 healthy adult participants and lasted up to 12 days. The main goal was to measure drug levels in the blood to check for interactions and ensure safety.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Celerion

    Tempe, Arizona, 85283, United States

Conditions

Explore the condition pages connected to this study.